NDA (Uganda)

NDA (National Drug Authority) is the Republic of Uganda's national regulatory authority responsible for the regulation of human + veterinary medicines + medical devices + cosmetics. NDA was established under the National Drug Policy and Authority Act Cap 206 of 1993 + operates as a body corporate under the Ministry of Health with headquarters in Kampala (Plot 19 Lumumba Avenue, Nakasero). NDA's statutory mandate includes ensuring the availability at all times of essential, efficacious + cost-effective drugs to the entire population of Uganda — an unusual mandate for a regulator that combines a product-safety + access role + reflects Uganda's 1990s health-system priorities of essential-medicines access alongside quality regulation.

NDA's organisational structure includes:

• Secretary — chief executive appointed by the Minister of Health + accountable to the NDA Board; serves a fixed term renewable.
• National Drug Authority Board — chaired by a Ministerial appointee + including the Secretary + representatives of the Pharmaceutical Society of Uganda + Uganda Medical Association + Ministry of Health + Ministry of Agriculture (veterinary medicines) + civil society.
• Directorate of Product Assessment + Registration — drug + biological + biosimilar + vaccine + herbal-medicine + veterinary-medicine + cosmetic registration.
• Directorate of Inspectorate + Enforcement — GMP / GDP / GCP inspection of Ugandan + foreign facilities + ports-of-entry + counterfeit-medicine enforcement.
• Directorate of Pharmacovigilance + Clinical Trials — National Pharmacovigilance Centre + clinical-trial oversight + ADR reporting + signal detection + Med Safety App (Uganda).
• Directorate of National Drug Quality Control Laboratory (NDQCL) — operates the NDQCL at Mulago (pursuing WHO Prequalification of Quality Control Laboratories status).
• Directorate of Medical Devices + Cosmetics — medical-device + IVD + cosmetic registration + classification + post-market materiovigilance.
• Directorate of Veterinary Medicines — veterinary-medicine registration jointly with the Ministry of Agriculture, Animal Industry and Fisheries.
• Directorate of Corporate Services + ICT — finance, ICT, HR + administration.
• Directorate of Communication + Public Affairs — consumer education + risk communication + media relations.

NDA's consolidated product-regulator model (covering medicines + devices + diagnostics + cosmetics + veterinary medicines under a single agency) is shared with peer EAC NRAs (Kenya PPB + Tanzania TMDA + Rwanda FDA) reflecting common-law colonial-era legislative inheritance + East African regulatory tradition. Unlike Kenya PPB, NDA does NOT regulate pharmacy practice or pharmacy premises licensing — those functions sit with the Pharmacy Council of Uganda + the Allied Health Professionals Council. Unlike Tanzania TMDA, NDA retains responsibility for veterinary medicines + has a broader essential-medicines-access mandate.

NDA is distinct from + complementary to: the Pharmaceutical Society of Uganda (PSU, a professional body advocating for pharmacists); the Uganda Medical and Dental Practitioners Council (UMDPC, which regulates medical + dental practice); the Allied Health Professionals Council (AHPC, which regulates pharmacy technicians + allied professions); the National Medical Stores (NMS, which procures + distributes medicines to public health facilities); the Joint Medical Store (JMS, which procures + distributes medicines to private not-for-profit facilities); the Uganda National Bureau of Standards (UNBS, which regulates non-pharmaceutical industrial standards); + the Uganda Virus Research Institute (UVRI, which conducts virology research + collaborates on clinical trials).

Legal foundations are the National Drug Policy and Authority Act Cap 206 of 1993, the NDA Guidelines on Submission of Documentation for Registration of Human Medicinal Products, the NDA Good Manufacturing Practice Guidelines, the NDA Medical Devices and IVDs Guidelines + a substantial body of NDA technical guidelines.

NDA is pursuing WHO Maturity Level 3 (ML3) under the WHO Global Benchmarking Tool framework + has indicated intention to achieve ML3 for vaccines + medicines as a near-term milestone. NDA has applied for PIC/S Membership + is an active participant in WHO PQ CRP, EAC-MRH, AMRH + ICDRA.

Ugandan pharmaceutical regulation operates under a layered framework of primary legislation + NDA guidelines:

• National Drug Policy and Authority Act Cap 206 of 1993 — primary legislation establishing NDA + its functions, powers + governance; provides for Board appointment + Secretary + the unique essential-medicines-access mandate combined with product regulation.
• National Drug Policy 2002 (under review) — overarching policy framework for medicines access + quality + rational use.
• Public Health Act Cap 281 — public-health framework including notifiable diseases + pharmacovigilance underpinning.
• Pharmacy and Drugs Act Cap 280 — pharmacy practice framework (administered by Pharmacy Council of Uganda separately from NDA).
• Counterfeit Goods Act 2010 — counterfeit goods framework with NDA cooperation on counterfeit-medicine enforcement.
• NDA Guidelines on Submission of Documentation for Registration of Human Medicinal Products — current registration framework for medicines + biologicals + biosimilars + vaccines.
• NDA Guidelines for Registration of Herbal + Complementary Medicinal Products — herbal medicines + nutraceuticals framework.
• NDA Good Manufacturing Practice Guidelines — current Ugandan GMP guidelines substantively aligned with WHO TRS 986 Annex 2 + ICH Q7 + EU GMP; mandatory for Ugandan + foreign manufacturers exporting to Uganda.
• NDA Good Clinical Practice Guidelines — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in Uganda.
• NDA Good Distribution Practice Guidelines — substantively aligned with WHO + EU GDP.
• NDA Pharmacovigilance Guidelines + Uganda National Pharmacovigilance System Strategic Plan — substantively aligned with WHO + EU GVP Modules; Uganda operates the Med Safety App + Yellow Form + ADR reporting.
• NDA Medical Devices and IVDs Guidelines — risk-based Class A-D framework substantively aligned with GHTF/IMDRF + EU MDR + ISO 13485 with Ugandan-specific overlay.
• NDA Cosmetics Guidelines — registration + labelling + safety substantiation for cosmetics + cosmetovigilance reporting.
• NDA Variations Guidelines — Type IA / IB / II variations procedure substantively similar to WHO + EU + EAC-MRH variations framework.
• NDA Promotion and Advertisement of Medicines Guidelines — pre-approval of medicines + medical-device advertising + promotional materials.
• NDA Veterinary Medicines Guidelines — veterinary-medicine registration jointly with the Ministry of Agriculture.

Uganda's National Drug Quality Control Laboratory (NDQCL) is operated by NDA + located at Mulago in Kampala. NDQCL is pursuing WHO Prequalification of Quality Control Laboratories status + already provides substantial pre-registration + post-market quality-control testing for NDA + serves regional procurement programmes.

• WHO Prequalification Pursuit — NDQCL is in the WHO Prequalification of Quality Control Laboratories pipeline + is pursuing WHO PQ-Lab designation; would join NQCL Kenya + NCQAL Tanzania as the third East African WHO-prequalified pharmaceutical quality-control laboratory.
• NDA regulatory laboratory — NDQCL conducts pre-registration quality testing + post-market surveillance testing + lot-release testing on behalf of NDA; results are direct NDA regulatory evidence.
• Procurement support — NDQCL provides quality-control testing for the National Medical Stores (NMS) + Joint Medical Store (JMS) + Gavi + Global Fund + USAID procurement programmes serving Uganda + the East African Community.
• ISO/IEC 17025 pursuit — NDQCL is pursuing ISO/IEC 17025 accreditation for pharmaceutical chemical + microbiological + biological testing; accreditation status is a precondition for WHO PQ-Lab designation.
• Counterfeit-medicine forensics — NDQCL conducts forensic chemical analysis on suspect counterfeit medicines + supports NDA Inspectorate + Uganda Police Force enforcement.
• Regional reference role — once WHO PQ-Lab designated, NDQCL will provide quality-control testing services for EAC Partner States that lack in-country WHO-prequalified laboratory capacity + supports EAC-MRH regional pharmacovigilance.
• Capacity-building role — NDQCL hosts training programmes for Ugandan + regional pharmaceutical analysts + contributes to WHO + AUDA-NEPAD regulatory-strengthening initiatives.
• Mulago co-location advantage — NDQCL's co-location with Mulago National Referral Hospital + Makerere University College of Health Sciences provides academic + clinical research collaboration + workforce development pipeline.

NDA medical-device + IVD regulation operates under the NDA Medical Devices and IVDs Guidelines with a Class A-D risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint a Ugandan Authorised Representative (UAR).

• Risk-based Classification (Class A / B / C / D + IVD Class A-D) — substantively aligned with GHTF/IMDRF + EU MDR/IVDR with Ugandan-specific overlay.
• Registration Certificate — issued by NDA Directorate of Medical Devices + Cosmetics based on technical-file review + Ugandan Authorised Representative designation + English labelling (Luganda + other Ugandan-language labelling optional but encouraged for consumer products).
• Ugandan Authorised Representative (UAR) — Ugandan-resident legal entity required for foreign manufacturers; bears post-market materiovigilance responsibility + Ugandan regulatory interface.
• ISO 13485:2016 — recognised by NDA as QMS evidence framework; Ugandan-specific overlay required including Ugandan quality records + UAR QMS interface.
• Reliance pathways — NDA accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• MDSAP — Uganda is not currently an MDSAP Participating Regulator + does not accept MDSAP audit reports as direct QMS evidence; ISO 13485 + Ugandan-specific overlay required.
• Post-market Materiovigilance — NDA operates medical-device adverse-event reporting through the Med Safety App + Yellow Form; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under NDA Cosmetics Guidelines require registration + Ugandan-specific labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting (including skin-lightening + mercury + hydroquinone safety).
• Ugandan UDI — NDA has not implemented full UDI equivalent to FDA UDI or EU EUDAMED UDI; Ugandan-specific labelling + product-identification requirements apply.
• Importation Permit — NDA Importation Permit required in addition to registration for foreign-manufactured devices entering Uganda.

NDA operates an active pharmacovigilance system through the National Pharmacovigilance Centre under the Directorate of Pharmacovigilance + Clinical Trials. Uganda adopted the Med Safety App model from Kenya PPB + has substantially expanded ADR reporting volume + diversity since the app's Uganda launch.

• Med Safety App Uganda — NDA adopted the Med Safety App model from Kenya PPB; mobile-app-based pharmacovigilance reporting available on iOS + Android in English + Luganda + Runyankole-Rukiga; substantially expanded ADR reporting volume + healthcare-professional + consumer participation.
• Yellow Form — paper-based ADR reporting form available in English + Luganda + distributed through healthcare facilities + pharmacies.
• National Pharmacovigilance Centre (NPC) — NDA Directorate of Pharmacovigilance + Clinical Trials operates the NPC + conducts ADR signal detection + risk-benefit analysis + risk communication.
• WHO PIDM Member — Uganda is a long-standing WHO Programme for International Drug Monitoring member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• E2B(R3) ICSR — NDA accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); NDA-specific submission timeline + Ugandan-population focus.
• Active surveillance — NDA operates targeted active-surveillance programmes including for HIV antiretrovirals + malaria + tuberculosis medicines + COVID-19 vaccines + sentinel-site hospital surveillance through Mulago + Mbarara + Gulu + Jinja regional referral hospitals.
• Cosmetovigilance — NDA operates cosmetovigilance reporting including for skin-lightening + mercury + hydroquinone cosmetic safety issues which are particularly prominent regulatory concerns in Uganda.

• WHO Maturity Level — NDA is pursuing WHO Maturity Level 3 (ML3) under the WHO Global Benchmarking Tool framework; ML3 ambition for vaccines + medicines as near-term milestone.
• WHO PQ Collaborative Registration Procedure (CRP) — active WHO PQ CRP Recipient with substantial use of CRP for vaccines + HIV + malaria + tuberculosis + reproductive-health medicines.
• WHO PQ Laboratory Pursuit — NDQCL is in the WHO Prequalification of Quality Control Laboratories pipeline + would join NQCL Kenya + NCQAL Tanzania as the third East African PQ-Lab.
• WHO PIDM (Programme for International Drug Monitoring) — long-standing Uganda membership; substantial VigiBase ADR contribution.
• AUDA-NEPAD AMRH — leading participant in African Medicines Regulatory Harmonisation programme; co-leads EAC-MRH work-stream alongside TMDA + PPB + Rwanda FDA.
• EAC-MRH (East African Community Medicines Regulatory Harmonisation) — NDA is a leading EAC NRA + co-leads EAC-MRH Joint Assessment Procedure across 6 EAC Partner States (Kenya + Tanzania + Uganda + Rwanda + Burundi + South Sudan; + DR Congo since 2022).
• African Medicines Agency (AMA) — AU continental medicines agency under AMA Treaty (entered into force November 2021); Uganda is an AMA Member State + participates in AMA Secretariat work-streams.
• PIC/S Application — NDA has applied for PIC/S Membership; NDA GMP Guidelines + inspectorate practices substantively aligned with PIC/S GMP Guide + Annexes.
• ICDRA Member — active International Conference of Drug Regulatory Authorities participant; hosts ICDRA-related Africa-Region preparatory meetings.
• ICH Observer — NDA is an ICH Observer; ICH guidelines extensively referenced in Ugandan regulatory practice.
• Bilateral MoUs — NDA holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + ANVISA + NMPA + MFDS + NAFDAC + Ghana FDA + SAHPRA + Egyptian EDA + TMDA + PPB + Rwanda FDA + Burundian + South Sudanese counterparts.
• Gavi / Global Fund / Gates Foundation / USAID / PEPFAR cooperation — NDA works closely with Gavi (vaccine procurement), Global Fund (HIV/TB/malaria procurement), Gates Foundation (regulatory strengthening) + USAID (PEPFAR + maternal-child health programmes); NDQCL serves procurement programmes.
• IMDRF Affiliate — NDA is an IMDRF Affiliate Member + draws on IMDRF guidance for medical-device regulation.

• Ugandan Authorised Representative or local Sponsor not properly designated — application rejected at NDA intake or post-approval compliance failure.
• Ugandan-specific labelling deficiencies — English labelling + Ugandan-Shilling pricing-reference + Ugandan PIL + storage-condition Ugandan-climate appropriateness; Luganda + Runyankole-Rukiga + other Ugandan-language labelling optional but encouraged for consumer products.
• GMP Guidelines gaps — applicants assuming EU GMP / PIC/S GMP compliance is sufficient without addressing Uganda-specific NDA GMP Guidelines + NDA-specific clarifications.
• Ugandan climate-zone stability data missing — Ugandan Climate Zone IVa/IVb (hot + humid tropical highland; Lake Victoria basin) stability data required for medicines + biologicals; many EU-only + US-only stability packages insufficient.
• WHO PQ CRP eligibility not leveraged — WHO-PQ-approved products eligible for accelerated CRP review at NDA; missed opportunity for substantial review time + cost reduction.
• EAC-MRH joint assessment not leveraged — EAC-MRH joint assessment + reliance pathway underutilised by applicants targeting multiple East African Community markets.
• Pharmacy practice scope misunderstood — unlike Kenya PPB, NDA does NOT regulate pharmacy practice or premises licensing (handled by Pharmacy Council of Uganda + Allied Health Professionals Council); avoid filing practice applications to NDA.
• Veterinary medicines coordination gap — NDA regulates veterinary medicines jointly with the Ministry of Agriculture, Animal Industry and Fisheries; sponsors must engage both authorities + comply with veterinary-specific dossier + residue + withdrawal-period requirements.
• Essential-medicines-access mandate underestimated — NDA's statutory mandate uniquely combines product safety with essential-medicines access for Uganda's population; pricing + access considerations may influence registration decisions for essential-medicines categories.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to WHO but with Uganda-specific timelines + fee structure.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Importation Permit not obtained — NDA Importation Permit required in addition to registration for foreign-manufactured medicines + devices entering Uganda.
• Port-of-entry inspection gaps — NDA Inspectorate inspection at Entebbe International Airport + inland container depots + land borders; importer logistics planning must account for inspection clearance time + Uganda's landlocked geography (Mombasa-Kampala + Dar es Salaam-Kampala corridors).
• Pharmacovigilance reporting gaps — NDA Pharmacovigilance + Med Safety App requirements substantively similar to WHO GVP + EU GVP but with Ugandan-specific format requirements + Ugandan-population pharmacovigilance focus + Luganda-language ICSR option.
• Clinical trial UNCST gap — Ugandan clinical trials require NDA CTA + UNCST-registered REC + UNCST (Uganda National Council for Science and Technology) authorisation; sponsors sometimes overlook the UNCST step.

V5 Ultimate provides the operational infrastructure Ugandan + foreign-supplier sites need for National Drug Policy and Authority Act Cap 206 + NDA GMP Guidelines + NDA Drug Registration + NDA Medical Devices Guidelines + EAC-MRH + WHO PQ CRP + Med Safety App + NDQCL readiness.

• NDA GMP Guidelines control framework — WHO TRS 986 Annex 2 + ICH Q7 + EU GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Uganda-specific clarifications + Ugandan climate-zone IVa/IVb stability monitoring.
• NDA drug-registration packaging — Ugandan CTD-aligned dossier structure with Uganda Module 1 specifics + Module 3 stability + Ugandan PIL + English labelling + optional Luganda/Runyankole-Rukiga labelling + Ugandan Authorised Representative declarations.
• WHO PQ CRP workflow — CRP Recipient packaging with WHO PQ Assessment Report + NDA-specific overlay + reduced dossier + accelerated 90-day review path.
• EAC-MRH workflow — EAC-MRH joint assessment + reliance pathway packaging for multi-country East African registration including Kenya + Tanzania + Uganda + Rwanda + Burundi + South Sudan + DRC.
• AMRH + AMA workflow — AU AMA + AUDA-NEPAD AMRH reliance pathway packaging for continental coverage.
• Ugandan Authorised Representative workflow — foreign-manufacturer UAR designation + role-management + Uganda-specific post-market surveillance + NDA interface.
• Ugandan clinical-trial workflow — NDA Good Clinical Practice + UNCST-registered REC + UNCST + UVRI cooperation + Uganda-population pharmacovigilance + NDA CTA submission + Ugandan SUSAR reporting.
• NDA Pharmacovigilance + Med Safety App Uganda integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Luganda-language ICSR option + NDA NPC + Med Safety App Uganda + VigiBase upload.
• Cosmetovigilance workflow — NDA Cosmetics Guidelines packaging + Ugandan cosmetic adverse-event reporting + Uganda-specific cosmetic regulation including skin-lightening / mercury / hydroquinone safety controls.
• Medical-device + cosmetic + nutraceutical workflow — NDA Medical Devices Guidelines + Cosmetics Guidelines + Nutraceutical Guidelines dossier packaging + Class A-D + IVD classification + ISO 13485 + Ugandan Authorised Representative + post-market materiovigilance.
• Veterinary-medicine workflow — NDA Veterinary Medicines Guidelines packaging + joint NDA + Ministry of Agriculture, Animal Industry and Fisheries submission + veterinary-specific dossier + residue + withdrawal-period evaluation.
• NDA Variations workflow — Type IA / IB / II classification + NDA procedure + Ugandan packaging.
• Renewal workflow — 5-year renewal window tracking + NDA procedure packaging.
• EAC + AU regional bridging — for companies operating across East Africa + Africa, V5 surfaces NDA + TMDA + PPB + Rwanda FDA + Burundi DPML + South Sudan DFDA + DRC ACOREP + NAFDAC + Ghana FDA + South African SAHPRA + Egyptian EDA harmonised dossier-element reuse alongside national-specific extensions.